Quintrio
Home

PHARMACEUTICAL PREPARATIONS

PMV Pharmaceuticals, Inc

PMVP

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Last trade $1.20
Day change +$0.01 (+0.84%)
Day range $1.08 – $1.30
Volume 651,182
Market cap $90M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$89.89M
Price / earnings
—
Price / book
1.57×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.91×

Profitability

Earnings per share
-$1.17
Return on assets
-79.47%
Return on equity
-155.03%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.81×
Quick ratio
9.81×
Cash ratio
1.87×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$69.64M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PMVP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4M$4.21M$3.69M$3.42M$4.31M$4.48M$4.12M$11.4M
Research and development$16.06M$14.68M$15.33M$15.83M$18.21M$18.4M$17.44M$13.77M
Total operating expenses$20.06M$18.88M$19.02M$19.24M$22.52M$22.88M$21.56M$25.17M
Operating income-$20.06M-$18.88M-$19.02M-$19.24M-$22.52M-$22.88M-$21.56M-$25.17M
Interest expense$0$0$0$1.23M$0$0$0$2.29M
Income before taxes-$34.38M-$18.08M-$18.04M-$18.01M-$21.07M-$21.21M-$19.63M-$23M
Income taxes-$7K$3K$0$26K-$6K$5K-$2.2M$0
Net income-$34.37M-$18.09M-$18.04M-$18.04M-$21.06M-$21.21M-$17.44M-$23M
Net income attributable to common shareholders-$34.37M-$18.09M-$18.04M-$18.04M-$21.06M-$21.21M-$17.44M-$23M
EBITDA-$20.04M-$18.86M-$18.99M-$19.21M-$22.49M-$22.85M-$21.53M-$25.13M
Basic earnings per share-$0.52-$0.34-$0.34-$0.34-$0.40-$0.41-$0.34-$0.44
Diluted earnings per share-$0.52-$0.34-$0.34-$0.34-$0.40-$0.41-$0.34-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026

PMV Pharmaceuticals announced that updated Phase 2 results from the PYNNACLE clinical trial of rezatapopt, a p53 reactivator for TP53 Y220C-positive advanced solid tumors, will be presented at the ENA 2026 symposium on November 20, 2026. The presentation will showcase efficacy data across multiple tumor types including ovarian, lung, breast, and endometrial cancers.

Zacks Investment Research

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know

PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.

GlobeNewswire Inc.

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMV Pharma announced a public offering of 22.055 million shares of common stock and pre-funded warrants to purchase 19.9 million shares, along with accompanying warrants, expected to raise approximately $50.8 million gross proceeds. The offering is priced at $1.21 per share and is expected to close on or about September 2, 2026.

GlobeNewswire Inc.

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals announced a leadership transition with Laurie Stelzer, a director since 2020, appointed as the new Board Chair, succeeding Rich Heyman effective June 4, 2026. Stelzer brings over 25 years of senior finance and business development experience in biopharmaceuticals. The transition occurs as the company continues enrollment in its PYNNACLE clinical trial for rezatapopt and prepares to submit a New Drug Application for platinum-resistant/refractory ovarian cancer patients in Q1 2027.

GlobeNewswire Inc.

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMV Pharmaceuticals reported positive Phase 2 interim data from its PYNNACLE trial evaluating rezatapopt for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations, achieving a 50% overall response rate among 48 evaluable patients. The company received FDA Orphan Drug Designation and plans to submit a New Drug Application in Q1 2027. However, cash runway extends only to Q2 2027 with $112.9 million in reserves, and the company increased R&D spending while net losses widened to $77.7 million in 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.